Abstract: The compounds of the formula (I) and their salts 1

Abstract: The present invention provides novel compounds, and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsey, irritable bowl syndrome, immune supression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction, inflammatory disorders, or fertility problems.

Abstract: Invented are G-CSF mimetics. Also invented are selected octacyclic compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds as G-CSF mimetics. Also invented are novel processes used in preparing these compounds.

Abstract: The invention is in the technical field of the crop protection agents, such as herbicides and plant growth regulators, in particular of the herbicides for the selective control of harmful plants in crops of useful plants.

Abstract: 2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 3-position being a substituted phenyl group and at the 2-position being a methyl cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.

Abstract: The invention relates to novel substituted arylsulphonyl(thio)ureas 1

Abstract: This invention relates generally to phenyl ether substituted triazines compounds and compositions containing same and their use to protect against degradation by environmental forces. A method for stabilizing a material by incorporating such triazines is also disclosed.

Abstract: The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Preferred tertiary-heteroalkylamine compounds are substituted N-heteroaryl-N-phenyl aminoalcohols.

Abstract: Lightfast additives for inkjet inks are provided. These additives exhibit excellent lightfastness of many dyestuffs (both water-soluble and water-insoluble). The lightfast additives exhibit good water solubility and significant effect on dye and pigment molecules which fade most when exposed to UV, ambient light, etc., and are suitable for improving permanence of inkjet inks, including thermal inkjet ink, piezo inkjet ink, and the like. The lightfast additive comprises a molecule which is composed of three parts or moieties: A-X—B, where (a) moiety A is an aryl sulfonic acid or aryl carboxylic acid, either in acid form or salt form, with or without substituents (e.g.

Abstract: Compounds of the formula (I) and their salts 1

Abstract: Isoxazolone compounds having the generic structure: 1

Abstract: The invention relates to the preparation of compounds (I) 1

Abstract: The present invention relates to novel red-shifted UV absorbers comprising 1,3,5-triazine structures containing a 2-naphthol-derived substituent. The present invention also relates to a method for stabilizing a material by incorporating into such material, e.g., organic material, the novel red-shifted triazine compounds in an amount effective to stabilize the material against the effects of actinic radiation.

Abstract: Indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating, e.g., kinases-dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds, and to methods of treating cancer as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, and psoriasis, by administering effective amounts of such compounds.

Abstract: The invention provides new processes for preparing compositions containing at least one triazine compound, including new compounds for use in these processes to form the compositions and the new compositions that are formed.

Abstract: The present invention describes novel pyrazolo[1,5-a]triazines of formula: wherein R3 is an alkyl, alkenyl, alkynyl, or cycloalkyl group, or pharmaceutically acceptable salt forms thereof, which are useful as CRF antagonists.

Abstract: This invention relates to a novel, efficient, economic and general-purpose process for isolating monophenolic-bisaryl triazine compounds from polyphenolic-triazines compounds and other impurities. More specifically, this invention relates to a process for isolating the monophenolic-bisaryl triazine compounds by contacting it with a base, an alcohol or a hydrocarbon solvent.

Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described.

Abstract: The invention relates to compounds of the formula as described herein and pharmaceutically acceptable acid addition salts thereof. The described compounds have a good affinity to the NK1 receptor.

Abstract: The present invention relates to novel heterocyclyl-containing diaryl sulfide compounds that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.

Abstract: The invention related to novel substituted arylsulphonyl(thio)ureas wherein: A is nitrogen or a CH grouping, Q is oxygen or sulphur, R1 is hydrogen, halogen or optionally substituted alkyl, alkoxy, alkylthio, alkylamino, dialkylamino, cycloalkyl, cycloalkyloxy or heterocyclyloxy, R2 is hydrogen, halogen or optionally substituted alkyl, alkoxy, alkylthio, alkylamino, dialkylamino, cycloalkyl, cycloalkyloxy or heterocyclyloxy, R3 is hydrogen or optionally substituted alkyl, R4 is optionally substituted alkyl, alkoxy, alkenyl, alkinyl, alkenyloxy, alkinyloxy, cycloalkyl, cycloalkyloxy or cycloalkylalkyl, and R5 is hydrogen, formyl or optionally substituted alkyl, alkylcarbonyl, alkoxycarbonyl, alkylsulphonyl, alkenyl, alkinyl, cycloalkyl, cycloalkylcarbonyl, cycloalkylsulphonyl or heterocyclyl, and salts of compounds of the formula (I), except for the compound N-(4,6-dimethyl-pyrimidin-2-yl)-N′-[2-(1,1,2,2-tetrafluoro-ethoxy)-6-methyl-phenylsulphonyl]-urea.

Abstract: The invention relates to novel pyridine derivatives of formula 1, to their preparation and to their use as medicaments, in particular for treating tumors.

Abstract: Optically active &bgr;-type tris-(2,3-epoxypropyl)-isocyanurate is obtained by a method of reacting isocyanuric acid with an optically active epihalohydrin, or a method of optically resolving a racemic modification of tris-(2,3-epoxypropyl)-isocyanurate by using an amylose or cellulose derivative. It is a method for producing a high melting point type tris-(2,3-epoxypropyl)-isocyanurate obtained by mixing two enantiomers of optically active &bgr;-type tris-(2,3-epoxypropyl)-isocyanurate.

Abstract: Triazine, benzotriazole and benzophenone derivatives which are substituted or bridged with polyoxyalkylene groups, according to claim 1, and their use as UV absorbers, especially in photographic materials, in inks, including inkjet inks and printing inks, in transfer prints, in paints and varnishes, organic polymeric materials, plastics, rubber, glass, packaging materials, in sunscreens of cosmetic preparations and in skin protection compositions.

Abstract: The invention is in the technical field of the crop protection agents, such as herbicides and plant growth regulators, in particular of the herbicides for the selective control of harmful plants in crops of useful plants.

Abstract: Sulfonylureas of the general formula I where R1 is a methyl or ethyl group; R2 is C1-C3-alkoxycarbonyl, a C1-C2-alkyl group which carries 1 to 5 fluorine atoms, methylsulfonyl, dimethylaminosulfonyl, thiomethyl, methylsulfinyl, methylsulfonyloxy, trifluoromethoxy, difluoromethoxy, difluorochloromethoxy, difluorochloromethyl or nitro; R3 is hydrogen, methyl, methoxy, ethoxy, fluorine, chlorine or thiomethyl; W is hydrogen or chlorine and Z is CH or N and their agriculturally utilizable salts are described.

Abstract: This invention concerns the compounds of formula the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein R1 and R2 are each independently selected from hydrogen; hydroxy; amino; optionally substituted C1-6alkyl; C1-6alkyloxy; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl; Ar1; mono- or di(C1-6alkyl)amino; mono- or di(C1-6alkyl)-aminocarbonyl; dihydro-2(3H)-furanone; or R1and R2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C1-6alkyl)amino-C1-4alkylidene; R3 is hydrogen, Ar1, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxycarbonyl, C1-6alkyl substituted with C1-6alkyloxycarbonyl; and R4, R5, R6, R7 and R8 are each independently selected from hydrogen, halo, C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalomethyloxy; L is optionally substituted C1-10alkyl; C3-10alkenyl; C3-10alkynyl; C3-7cycloalkyl; Ar1is optionally substituted phenyl; for the manufacture of a medicine for the t

Abstract: Sulfonylureas of the general formula I 1

Abstract: Disclosed are compounds of the formula: where R1, R2, R3, R4, R5, R6, and X are defined herein. These compounds are selective modulators of NPY1 receptors. These compounds are useful in the treatment of a number of CNS disorders, metabolic disorders, and peripheral disorders, particularly eating disorders and hypertension. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of NPY1 receptors and as standards in assays for NPY1 receptor binding. Methods of using the compounds in receptor localization studies are given.

Abstract: This invention relates aryl substituted pyridines, pyrimidines, pyrazines and triazines of Formula I: 1

Abstract: Corticotropin releasing factor (CRF) antagonists of formula I or II: and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.

Abstract: Quaternary ammonium compounds having at least two fiber reactive sites and at least two dye reactive sites, and processes for making and using the same are disclosed. The compounds of the invention can advantageously be used in a cellulosic fabric pretreatment process to allow anionic dyeing without requiring salt to exhaust or drive the dye into the cellulosic fiber.

Abstract: Invented are G-CSF mimetics. Also invented are selected octacyclic compounds, pharmaceutical compositions containing these compounds, and methods of using these compounds as G-CSF mimetics. Also invented are novel processes used in preparing these compounds.

Abstract: A compound of formula (I) wherein X is a —CONHOH group and the R groups are defined in the claims. The compounds are inhibitors of matrix metalloproteinases involved in tissue degradation and inhibitors of the release of tumour necrosis factor from cells.

Abstract: The present invention provides novel compounds, and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsey, irritable bowl syndrome, immune supression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction, inflammatory disorders, or fertility problems. The novel compounds provided by this invention are those of formula: wherein R1, R3, R5, Q, Z, Y, V, X and X′ are as defined herein.

Abstract: Hexahydrotriazine compounds of the formula: 1

Abstract: A hydrazone dye is provided which forms cyan color having an excellent hue. The hydrazone dye is expressed by the following general formula (I): wherein Ar represents an aryl group or a heterocyclic group; R1 through R4 each represent a hydrogen atom, a halogen, —CN, —NH2, —NO2, —OH, —CO2H, —SO3H, a quaternary ammonium group, —CO2M1/n, —SO3M1/n, an alkyl group, alkenyl group, alkynyl group, aryl group, acyl group, carbamoyl group, sulfamoyl group, alkoxycarbonyl group, aryloxycarbonyl group, acyloxy group, alkoxy group, aryloxy group, alkylthio group, arylthio group, alkylsulfonyl group, arylsulfonyl group, alkylphosphoryl group, arylphosphoryl group, or a substituted amino group; M represents a metal atom; and n represents an integer from 1 to 4.

Abstract: Corticotropin releasing factor (CRF) antagonists of formula I or II: and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.

Abstract: Compounds of the formula (I) and salts thereof in which R1 to R6, W, X, Y and Z are defined as in claim 1, have herbicidal or plant growth-regulatory properties. They can be prepared by processes analogous to known processes (cf. claim 5), in some cases via novel intermediate products (cf.

Abstract: A compound of the Formula (1) and salts thereof: wherein: Ar, Ar1, J, J1, X, X1 W, W1, L and m are as defined in the description. The compounds of Formula (1) are useful as additives in inks, especially ink jet printing inks, for reducing color bleed between adjacent printed regions. Also claimed are inks containing a compound of the Formula (1), a method of ink jet printing using the inks, a substrate printed with the ink and an ink jet printer cartridge containing the ink.

Abstract: Corticotropin releasing factor (CRF) antagonists of formula I or II: and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.

Abstract: The invention provides amide derivatives which are useful as analgesics, anti-inflammatory agents, antimicrobial drugs, hypoglycemic agents, hypolipidemic agents, antihypertensive agents, anti-cancer agents, etc., the derivatives being represented by the formula ##STR1## wherein ring A represents a benzene ring, a naphthalene ring, a pyridine ring or a furan ring; R.sup.4 represents a heterocyclic group selected from the group consisting of a lower alkyl-substituted thieno[3,2-d]pyrimidin-4-yl group, an optionally substituted pyrazolo[1,5-a]-1,3,5-triazin-4-yl group, a pyrazolo[3,4-d]pyrimidin-4-yl group substituted at the 6-position and a purin-6-yl group substituted at the 2-position; and R.sup.

Abstract: Compounds of the formula I or salts thereof, in whichX is oxygen, --O--NR.sup.2 -- or --SO.sub.2 --NR.sup.2 --, and Y is N or CH,R.sup.1 is (C.sub.1 -C.sub.6)alkyl, (C.sub.2 -C.sub.6)alkenyl or (C.sub.2 -C.sub.6)alkynyl, which are in each case optionally substituted, or, in the case where X=oxygen, also (subst.) phenyl,R.sup.2 is H, (C.sub.1 -C.sub.6)alkyl, (C.sub.2 -C.sub.6)alkenyl or -alkynyl or (C.sub.3 -C.sub.6)cycloalkyl,R.sup.3 and R.sup.4 are H, (subst.) (C.sub.1 -C.sub.4)alkyl or (subst.) (C.sub.1 -C.sub.4)alkoxy or halogen, (C.sub.1 -C.sub.4)alkylthio, (C.sub.1 -C.sub.4)-alkylamino or di[(C.sub.1 -C.sub.4)alkyl]-amino,R.sup.5 is H or (C.sub.1 -C.sub.4)alkyl and R.sup.6 is hydrogen,may be prepared by reacting compounds of the formula II,R.sup.1 --X--R.sup.7 (II)with compounds of the formulae III, IV and VR.sup.8 --OCN (III)SO.sub.2 Cl.sub.2 (IV) ##STR1## where R.sup.7 and R.sup.8 are H, a quarternary ammonium ion or one equivalent of a metal cation.

Abstract: A composition which includes the following compounds: ##STR1## wherein R.sup.1, which may be the same or different, is a hydrophilic group;R.sup.2, which may the same or different, is selected from the group consisting of electron donating groups, electron withdrawing groups, and electron neutral groups;R.sup.3 is a substituted or unsubstituted, positively charged heteroaromatic ring linked to the triazine backbone through a nitrogen atom in the R.sup.3 ring; andX.sup.- is a counterion.If R.sup.3 is an unsubstituted pyridine, the counterion X.sup.- may be selected from any counterion other than Cl.sup.- and OH.sup.-. Otherwise, the counterion X.sup.- may be selected from any counterion.The compound may be applied to a substrate to form a birefingent optical retardationdevice. The retardationdevice may be used in display devices such as computers and the like to correct the phase and polarization states of the display's emitted light and improve image quality at viewing angles away from the normal.

Abstract: A polymeric article, such as an extruded or molded article or a biaxially oriented tape or film, and a method of stabilizing such a polymeric article to protect the article from degradation due to exposure to UV light. The article is formed by blending a polymeric material with from about 50 to about 5,000 ppm of at least one ortho hydroxy tris-aryl triazine light absorber and from about 500 ppm to about 1.25 percent of at least one oligomeric, polymeric, or high molecular weight HALS having a molecular weight of at least about 500, wherein the weight ratio of HALS to triazine light absorber is from about 3:1 to about 20:1, to form a stabilized polymeric composition, and forming an extruded or molded article or a biaxially oriented tape or film from the stabilized polymeric composition.

Abstract: Sulfonylureas of the general formula I ##STR1## where R.sup.1 is a methyl or ethyl group;R.sup.2 is C.sub.1 -C.sub.3 -alkoxycarbonyl, a C.sub.1 -C.sub.2 -alkyl group which carries 1 to 5 fluorine atoms, methylsulfonyl, dimethylaminosulfonyl, thiomethyl, methylsulfinyl, methylsulfonyloxy, trifluoromethoxy, difluoromethoxy, difluorochloromethoxy, difluorochloromethyl or nitro;R.sup.3 is hydrogen, methyl, methoxy, ethoxy, fluorine, chlorine or thiomethyl;W is hydrogen or chlorine andZ is CH or Nand their agriculturally utilizable salts are described.

Abstract: The process for crosslinking cellulosic fiber materials, especially cellulosic fiber materials which are 20 to 100% by weight natural or regenerated cellulose fibers, comprises applying to the cellulosic fiber materials in which the cellulosic fibers comprise natural or regenerated cellulose at least one product of the general formula (1) ##STR1## where A is a colorless aliphatic, aromatic or heteroaromatic radical, R is a fiber-reactive radical and n is 1, 2, 3 or 4, with the proviso that the radical [R].sub.n includes at least two fiber-reactive groups, and is useful for achieving permanent finish effects, for example in the area of easy care, dimensional stability and shrink resistance.

Abstract: The compounds of the s-triazine series of formula I ##STR1## wherein the symbols R.sub.1, R.sub.2, R.sub.3, X and n possess the significances given in claim 1, are eminently suitable, when applied to textile material, as UV-absorbers, as resist agents for anionic dyes, and as stain blockers.

Abstract: The invention relates to the use of .alpha.-hydroxyketoalkyl derivatives as light protection filters for cosmetic or pharmaceutical products, the .alpha.-hydroxyketoalkyl group being linked, if appropriate via a spacer, to a chromophoric group which has an absorption maximum in a wavelength range of between 280 and 400 nm and has a conjugated .pi.-electron system of at least 8 .pi.-electrons, and to new .alpha.-hydroxyalkyl derivatives, processes for their preparation and pharmaceutical and cosmetic formulations comprising these derivatives as light protection substances.

Abstract: Carboxylic acid derivatives ##STR1## where R-R.sup.6, X, Y and Z have the meanings stated in the description, and the preparation thereof, are described. The novel compounds are suitable for controlling diseases.